Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Takayasu's Arteritis: early-phase trial registry

2 of 5 indexed Takayasu's Arteritis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Takayasu's Arteritis: 5 US clinical trials tracked, 2 recruiting.

Takayasu's Arteritis is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), running 2 of these trials.

Enrollment posture brief

Registry condition takayasus-arteritis

OPEN 2 | RECR 40% | LATE 0 | EARLY 1 | RANK #3391 | SPON 2

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Takayasu's Arteritis (this)40%
Open-enrollment share among volume-matched conditions near Takayasu's Arteritis

Takayasu's Arteritis lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Takayasu's Arteritis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Takayasu's Arteritis is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Takayasu's Arteritis research.

    National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) accounts for 2 of 5 trials (40%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Typical Takayasu's Arteritis enrolment sits around 707 participants.

    Median target enrolment is 707 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.

  4. Takayasu's Arteritis research leans observational.

    1 interventional and 4 observational studies make up this index (20% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Takayasu's Arteritis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Abatacept Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Takayasu's Arteritis trials. A trial with sites in several states counts in each.

Utah 3 trials
Pennsylvania 3 trials
Ohio 3 trials
Minnesota 3 trials
New York 2 trials
Maryland 2 trials
Massachusetts 2 trials
California 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Takayasu's Arteritis page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Takayasu's Arteritis condition card totals 5 registered trials; most-linked intervention Abatacept; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.